Form 6K argenx NV ADR For: 20 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Argen-X (ARGX)
Argen-X stock price live, this page displays EBR ARGX stock exchange data. View the ARGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Argen-X real time stock price chart below.
What Is the Argen-X Stock Price Today?
The Argen-X stock price today is 584.80.
What Is the Stock Symbol for Argen-X?
The stock symbol for Argen-X is "ARGX."
What Stock Exchange Does Argen-X Trade On?
Argen-X is listed and trades on the Brussels stock exchange.
Is Argen-X a Good Stock to Buy?
Determining whether Argen-X—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: NL0010832176)
What Is the Argen-X Stock Price Today?
The Argen-X stock price today is 584.80.
What Is the Stock Symbol for Argen-X?
The stock symbol for Argen-X is "ARGX."
What Stock Exchange Does Argen-X Trade On?
Argen-X is listed and trades on the Brussels stock exchange.
Is Argen-X a Good Stock to Buy?
Determining whether Argen-X—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: NL0010832176)
584.80
-8.40(-1.42%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
584.80
601.80
52 wk Range
456.60
810.00
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
584.80601.80
52 wk Range
456.60810.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARGX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
839.27
Upside
+43.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
- Form 6K argenx NV ADR For: 20 March
- Investing.com
- Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Compare ARGX to Peers and Sector
Metrics to compare | ARGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 32.5x | 27.1x | −0.5x | |
PEG Ratio | 0.61 | 0.46 | 0.00 | |
Price/Book | 5.7x | 3.8x | 2.6x | |
Price / LTM Sales | 9.9x | 3.0x | 3.1x | |
Upside (Analyst Target) | 48.8% | 48.3% | 57.5% | |
Fair Value Upside | Unlock | 25.0% | 8.1% | Unlock |
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 839.27
(+43.51% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
6.80 / 5.07
Revenue / Forecast
1.12B / 1.1B
People Also Watch
FAQ
What Is the Argen-X (ARGX) Stock Price Today?
The Argen-X stock price today is 584.80 EUR.
What Stock Exchange Does Argen-X Trade On?
Argen-X is listed and trades on the Brussels Stock Exchange.
What Is the Stock Symbol for Argen-X?
The stock symbol for Argen-X is "ARGX."
What Is the Argen-X Market Cap?
As of today, Argen-X market cap is 36.29B EUR.
What Is Argen-X's Earnings Per Share (TTM)?
The Argen-X EPS (TTM) is 19.57.
When Is the Next Argen-X Earnings Date?
Argen-X will release its next earnings report on May 07, 2026.
From a Technical Analysis Perspective, Is ARGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Argen-X Stock Split?
Argen-X has split 0 times.
How Many Employees Does Argen-X Have?
Argen-X has 1863 employees.
What is the current trading status of Argen-X (ARGX)?
As of Mar 23, 2026, Argen-X (ARGX) is trading at a price of 584.80 EUR, with a previous close of 584.80 EUR. The stock has fluctuated within a day range of 584.80 EUR to 601.80 EUR, while its 52-week range spans from 456.60 EUR to 810.00 EUR.
What Is Argen-X (ARGX) Price Target According to Analysts?
The average 12-month price target for Argen-X is 839.27 EUR, with a high estimate of 991 EUR and a low estimate of 600 EUR. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.51% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.